Market Overview:
The global acromegaly market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as increasing prevalence of acromegaly, rising awareness about the disease, and technological advancements in the field of acromegaly treatment. However, high cost of treatment is expected to restrain the growth of this market during the forecast period. The global acromegaly market is segmented by type into somatostatin analogues, dopamine agonists, growth hormone receptor antagonists, and other types. The somatostatin analogue segment is expected to dominate the global acromegaly market during the forecast period owing to its high efficacy and safety profile. On basis on application, hospitals are estimated account for majority share in terms revenue generated by end users followed clinics across all regions covered under this study except Asia Pacific where clinics are anticipated account for larger revenue share as compared hospitals during 2018-2030 timeframe .
Product Definition:
A hormonal disorder that results when the pituitary gland produces too much growth hormone. Acromegaly is most often caused by a benign tumor on the pituitary gland. The excessive growth hormone can cause enlargement of the hands, feet, and facial features. It can also lead to heart disease, diabetes, and other health problems.
Somatostatin Analogues:
Somatostatin Analogues, it's usage and growth factor in Acromegaly market? - The global somatostatin analogues, it's usage and growth factor in acromegaly market size was valued at USD 6.7 billion in 2015.
Dopamine Agonists:
Dopamine agonists are chemicals that bind to the Dopamine Receptor and block the action of Dopamine in the brain. They are used as anti-epileptic drugs, which prevent seizures by controlling or modifying abnormal neuronal activity during a seizure.
Application Insights:
The patient population that can be treated with somatostatin analogues or other dopamine agonists is generally above 15 years of age. The disease predominantly affects males and females equally. Acromegaly is a chronic disease, which means the treatment needs to be lifelong. Hence, the global acromegaly market by application is segmented into hospitals and clinics as well as private practices/hospitals. Hospitals dominate the market in terms of revenue share owing to factors such as high prevalence of patients suffering from acromegaly at one place and availability of healthcare professionals skilled in treating this condition at hospitals across countries globally.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of key players, favorable reimbursement policies, and increasing healthcare expenditure. The U.S., which accounted for a major share in North America, is expected to be one of the lucrative markets globally over the forecast period due to an increase in prevalence coupled with rising awareness about acromegaly treatment options among patients.
Asia Pacific is anticipated to witness significant growth during the forecast period owing to factors such as improving healthcare infrastructure and growing patient awareness regarding available treatment options for acromegaly. Moreover, increasing disposable income levels are also likely to contribute toward regional growth over this period. In addition, Japan accounts for a major share due its large population base suffering from acromegalic symptoms; hence boosting revenue generation within Asia Pacific region itself will depend on how fast new cases are diagnosed & treated within that country alone (Kawasaki et al., 2016).
Growth Factors:
- Increasing incidence of acromegaly due to rising prevalence of obesity and diabetes mellitus.
- Growing awareness about the disease and its symptoms among people.
- Rising demand for effective treatment options for acromegaly patients.
- Availability of novel therapies and treatments for the disease in the market.
Scope Of The Report
Report Attributes
Report Details
Report Title
Acromegaly Market Research Report
By Type
Somatostatin Analogues, Dopamine Agonists, Growth Hormone Receptor Antagonists, Other
By Application
Hospitals, Clinics
By Companies
Novartis, Aegis Therapeutics, Chiasma, Crinetics Pharmaceuticals, Daewoong Pharmaceutical, Peptron, Silence Therapeutics, Strongbridge Biopharma, Amryt Pharma, Foresee Pharmaceuticals, Glide Pharmaceutical, Ionis Pharmaceuticals, Ipsen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
193
Number of Tables & Figures
136
Customization Available
Yes, the report can be customized as per your need.
Global Acromegaly Market Report Segments:
The global Acromegaly market is segmented on the basis of:
Types
Somatostatin Analogues, Dopamine Agonists, Growth Hormone Receptor Antagonists, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Aegis Therapeutics
- Chiasma
- Crinetics Pharmaceuticals
- Daewoong Pharmaceutical
- Peptron
- Silence Therapeutics
- Strongbridge Biopharma
- Amryt Pharma
- Foresee Pharmaceuticals
- Glide Pharmaceutical
- Ionis Pharmaceuticals
- Ipsen
Highlights of The Acromegaly Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Somatostatin Analogues
- Dopamine Agonists
- Growth Hormone Receptor Antagonists
- Other
- By Application:
- Hospitals
- Clinics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Acromegaly Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Acromegaly is a disorder that results from the overproduction of growth hormone. This can cause abnormal enlargement of the hands, feet, face, and head. It can also lead to problems with bone density and strength.
Some of the major players in the acromegaly market are Novartis, Aegis Therapeutics, Chiasma, Crinetics Pharmaceuticals, Daewoong Pharmaceutical, Peptron, Silence Therapeutics, Strongbridge Biopharma, Amryt Pharma, Foresee Pharmaceuticals, Glide Pharmaceutical, Ionis Pharmaceuticals, Ipsen.
The acromegaly market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Acromegaly Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Acromegaly Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Acromegaly Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Acromegaly Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Acromegaly Market Size & Forecast, 2020-2028
4.5.1 Acromegaly Market Size and Y-o-Y Growth
4.5.2 Acromegaly Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Somatostatin Analogues
5.2.2 Dopamine Agonists
5.2.3 Growth Hormone Receptor Antagonists
5.2.4 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Acromegaly Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Acromegaly Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Somatostatin Analogues
9.6.2 Dopamine Agonists
9.6.3 Growth Hormone Receptor Antagonists
9.6.4 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Somatostatin Analogues
10.6.2 Dopamine Agonists
10.6.3 Growth Hormone Receptor Antagonists
10.6.4 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Somatostatin Analogues
11.6.2 Dopamine Agonists
11.6.3 Growth Hormone Receptor Antagonists
11.6.4 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Somatostatin Analogues
12.6.2 Dopamine Agonists
12.6.3 Growth Hormone Receptor Antagonists
12.6.4 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Somatostatin Analogues
13.6.2 Dopamine Agonists
13.6.3 Growth Hormone Receptor Antagonists
13.6.4 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Acromegaly Market: Competitive Dashboard
14.2 Global Acromegaly Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Aegis Therapeutics
14.3.3 Chiasma
14.3.4 Crinetics Pharmaceuticals
14.3.5 Daewoong Pharmaceutical
14.3.6 Peptron
14.3.7 Silence Therapeutics
14.3.8 Strongbridge Biopharma
14.3.9 Amryt Pharma
14.3.10 Foresee Pharmaceuticals
14.3.11 Glide Pharmaceutical
14.3.12 Ionis Pharmaceuticals
14.3.13 Ipsen
